Krystal Biotech Inc.(KRYS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KRYS Krystal Biotech Inc.

交易中 08-19 09:37:03 EDT

339.87

+7.05

+2.12%

最高340.22	最低335.44	成交量5,402
今开339.61	昨收332.82	日振幅1.44%
总市值100.60亿	流通市值80.00亿	总股本2,960万
成交额183.16万	换手率0.02%	流通股本2,354万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"KRYS","market":"US","secType":"STK","nameCN":"Krystal Biotech Inc.","latestPrice":339.8675,"timestamp":1787146620110,"preClose":332.82,"halted":0,"volume":5402,"delay":0,"changeRate":0.021175109668890132,"floatShares":23539300,"shares":29598836,"eps":7.965707,"marketStatus":"交易中","change":7.0475,"latestTime":"08-19 09:37:03 EDT","open":339.61,"high":340.22,"low":335.44,"amount":1831622.1073999999,"amplitude":0.014362,"askPrice":341.17,"askSize":10,"bidPrice":337.18,"bidSize":82,"shortable":3,"etf":0,"ttmEps":7.965707,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787169600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":332.82,"preHourTrading":{"tag":"盘前","latestPrice":339.61,"preClose":332.82,"latestTime":"09:29 EDT","volume":108,"amount":36634.1292,"timestamp":1787146199999,"change":6.79,"changeRate":0.020401,"amplitude":0.020401},"postHourTrading":{"tag":"盘后","latestPrice":332.82,"preClose":332.82,"latestTime":"19:34 EDT","volume":2549,"amount":848355.94,"timestamp":1787096051640,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.515149,"impliedVol":0.3612,"impliedVolPercentile":0.1434},"requestUrl":"/m/hq/s/KRYS","defaultTab":"news","newsList":[{"id":"1105101670","title":"异动解读｜Krystal Biotech盘中上涨5.04%，二季度盈利大超预期推动超跌反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1105101670","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105101670?lang=zh_cn&edition=full","pubTime":"2026-08-05 03:41","pubTimestamp":1785872473,"startTime":"0","endTime":"0","summary":"8月4日，Krystal Biotech盘中上涨5.04%，报328.31美元/股，成交额1.19亿美元。消息面上，公司于前一交易日盘前公布二季度财报后股价一度重挫逾9%，但市场逐步消化后出现反弹。财报显示，公司二季度每股收益1.79美元，大幅超出市场预期的1.62美元；净利润升至5480万美元，同比大增43%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135810660","title":"异动解读 | Krystal Biotech盘中大跌9.29%，二季度营收不及预期引发获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1135810660","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135810660?lang=zh_cn&edition=full","pubTime":"2026-08-03 23:22","pubTimestamp":1785770569,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.（KRYS）今日盘中股价大跌9.29%，引发市场广泛关注。消息面上，公司于盘前公布二季度财报，尽管每股收益1.79美元超出市场预期的1.62美元，但其旗舰产品VYJUVEK全球净销售额为1.192亿美元，低于市场一致预期的1.22亿美元，同比增速24%亦不及此前预期的32.72%。此外，公司一季度营收已达1.164亿美元，二季度环比增长有限，令市场对其商业放量节奏产生担忧。值得注意的是，Krystal Biotech近期刚被纳入标普400中型股指数，前期股价已有所透支。此次营收不及预期，叠加投资者对增长放缓的忧虑，引发了获利回吐，导致股价盘中大幅走低。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177957934","title":"异动解读｜Krystal Biotech盘中下跌5.31%，二季度营收不及预期引发获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1177957934","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1177957934?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:33","pubTimestamp":1785763980,"startTime":"0","endTime":"0","summary":"8月3日，Krystal Biotech盘中下跌5.31%，报327.14美元/股，成交额2611.25万美元。消息面上，公司于盘前公布二季度财报，尽管每股收益1.79美元超出市场预期的1.62美元，但旗舰产品VYJUVEK全球净销售额为1.192亿美元，低于市场一致预期的1.22亿美元，同比增速24%亦不及此前预期的32.72%。此外，公司一季度营收已达1.164亿美元，二季度环比增长有限，市场对其商业放量节奏产生担忧。叠加公司近期被纳入标普400中型股指数后前期股价已有所透支，营收不及预期引发获利回吐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech盘中下跌5.31%，二季度营收不及预期引发获利回吐","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134647704","title":"异动解读 | Krystal Biotech盘前大跌7.65%，二季度营收不及预期引发获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1134647704","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134647704?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:38","pubTimestamp":1785757100,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.今日盘前股价大跌7.65%，报315.54美元，成交额100.0万美元，引发市场广泛关注。消息面上，公司在盘前公布了二季度财报。此外，公司一季度营收已达1.164亿美元，二季度环比增长有限，令市场对其商业放量节奏产生担忧。值得注意的是，Krystal Biotech近期刚被纳入标普400中型股指数，前期股价已有所透支。此次营收不及预期，叠加投资者对增长放缓的忧虑，引发了获利回吐，导致股价在盘前大幅走低。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145040413","title":"异动解读｜Krystal Biotech盘前下跌7.65%，二季度营收不及市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1145040413","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145040413?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:37","pubTimestamp":1785757023,"startTime":"0","endTime":"0","summary":"8月3日，Krystal Biotech盘前下跌7.65%，报315.54美元/股，成交额100.0万美元。消息面上，公司于盘前公布二季度财报，尽管每股收益1.79美元超出市场预期的1.62美元，但旗舰产品VYJUVEK全球净销售额为1.192亿美元，低于市场一致预期的1.22亿美元，同比增速24%亦不及此前预期的32.72%。此外，公司此前一季度营收已达1.164亿美元，二季度环比增长有限，市场对其商业放量节奏产生担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Krystal Biotech盘前下跌7.65%，二季度营收不及市场预期","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375118","title":"Krystal Biotech（KRYS）二季度净利润升至5480万美元 同比大增43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375118","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656375118?lang=zh_cn&edition=full","pubTime":"2026-08-03 19:21","pubTimestamp":1785756096,"startTime":"0","endTime":"0","summary":"金吾财讯 | 全球基因药物领军企业 Krystal Biotech 公布 2026 年第二季度财务及运营业绩。得益于旗舰基因治疗药物 VYJUVEK 在全球市场的强劲销售，公司当季营收与净利润双双实现大幅增长，现金储备亦进一步充实。数据显示，当季净利润升至 5480 万美元，稀释每股收益 1.79 美元，相较去年同期的 3830 万美元大幅增长 43%。季度旗舰产品 VYJUVEK 全球净销售额达到 1.192 亿美元，同比增长 24%；自上市以来的累计销售额已达 9.659 亿美元。报告提到，VYJUVEK 目前已在美国、欧洲和日本获批。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/MGE2ZWRkM2ExNzliODFiMWYxODE0Mjk1MTc3MTQ2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGE2ZWRkM2ExNzliODFiMWYxODE0Mjk1MTc3MTQ2.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303327","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199316650","title":"异动解读｜Krystal Biotech盘前上涨6.36%，财报预期强劲叠加指数纳入催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1199316650","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199316650?lang=zh_cn&edition=full","pubTime":"2026-07-29 16:58","pubTimestamp":1785315522,"startTime":"0","endTime":"0","summary":"7月29日，Krystal Biotech盘前上涨6.36%，报387.38美元/股，成交额4.13万美元。消息面上，公司即将于8月3日盘前发布Q2财报，市场一致预期本季度营收为1.22亿美元，同比增长32.72%；调整后每股收益为1.69美元，同比增长49.59%；EBIT预计同比增长88.66%。此前Q1财报中EPS实际为1.83美元，大幅超出FactSet预期的1.44美元，多家机构随后上调盈利预测，市场情绪偏多。基本面方面，核心产品Vyjuvek此前获英国MHRA批准，海外商业化拓展持续推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读｜Krystal Biotech盘前上涨6.36%，财报预期强劲叠加指数纳入催化","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187477381","title":"财报前瞻｜Krystal Biotech Inc.Q2营收预计增32.72%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1187477381","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187477381?lang=zh_cn&edition=full","pubTime":"2026-07-27 09:05","pubTimestamp":1785114355,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.将于2026年08月03日美股盘前发布最新季度财报，本文梳理市场一致预期、上季表现与核心看点。市场一致预期本季度Krystal Biotech Inc.营收为1.22亿美元，同比增长32.72%；调整后每股收益为1.69美元，同比增长49.59%；EBIT为0.55亿美元，同比增长88.66%；公司在上一季度财报中未给出针对本季度的明确数值指引。在2026年第一季度业绩公布后，多家卖方机构上调了对Krystal Biotech Inc.的盈利与收入预测，舆论氛围以看多为主。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Krystal Biotech Inc.Q2营收预计增32.72%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154249418","title":"Krystal Biotech决定终止临床研究，以推动KB801进入关键性试验；SEC文件称未观察到安全性问题","url":"https://stock-news.laohu8.com/highlight/detail?id=1154249418","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154249418?lang=zh_cn&edition=full","pubTime":"2026-07-22 05:27","pubTimestamp":1784669234,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，Krystal Biotech Inc. 已决定终止一项临床研究，旨在将其候选药物KB801推进至关键性试验阶段。公司强调，此项决定并非基于任何安全性方面的考量，在研究中未观察到相关的安全性问题。\n该举措标志着公司对KB801开发策略的一次重要调整。通过提前终止当前研究，Krystal Biotech 计划更高效地集中资源，为后续更为关键的确证性试验阶段做准备。此举旨在加速该疗法的整体开发进程。\n公司表示，将继续对KB801项目保持专注，并致力于推进其临床开发计划。此次策略调整反映了公司在评估研发管线优先级和优化资源分配方面的持续努力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS","HELX","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169541881","title":"Krystal Biotech 披露：已终止研究无更多受试者数据更新，关键性试验结果将适时公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1169541881","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169541881?lang=zh_cn&edition=full","pubTime":"2026-07-22 05:27","pubTimestamp":1784669233,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的最新文件，Krystal Biotech Inc. 已明确表示，其一项已终止的研究将不再提供任何受试者层面的数据更新。公司同时指出，其关键性临床试验的最终结果将在适当的时候对外公布。\n这意味着，对于该特定研究项目，投资者及公众将无法期待获得更进一步的个体患者疗效或安全性细节。公司的研发重心与信息披露将集中于正在推进的关键性试验上，相关结果预计将按计划在未来适时发布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","PSCH","HELX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192230520","title":"标普道琼斯指数宣布：Krystal Biotech Inc.将取代Taylor Morrison Home Corporation进入标普400中型股指数","url":"https://stock-news.laohu8.com/highlight/detail?id=1192230520","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192230520?lang=zh_cn&edition=full","pubTime":"2026-07-21 05:18","pubTimestamp":1784582294,"startTime":"0","endTime":"0","summary":"标普道琼斯指数公司宣布，将对标普400中型股指数（S&P MidCap 400）的成分股进行调整。根据公告，Krystal Biotech Inc. 将取代 Taylor Morrison Home Corporation 成为该指数的新成员。\n此次成分股变动是标普道琼斯指数公司定期评估与调整的一部分。指数成分股的调整通常基于市值、流动性以及行业代表性等多种因素。此番调整反映了市场结构的变化以及相关公司的发展状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","HELX","PSCH","TMHC","BK4139","BK4088"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141970680","title":"Krystal Biotech宣布Vyjuvek®获英国MHRA批准用于治疗营养不良型大疱性表皮松解症","url":"https://stock-news.laohu8.com/highlight/detail?id=1141970680","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141970680?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:00","pubTimestamp":1779105630,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.  宣布，其基因疗法Vyjuvek已获得英国药品和保健品监管局的批准，适用于治疗营养不良型大疱性表皮松解症患者。英国监管机构的批准，是基于其先前在美国获得FDA批准以及一系列临床试验所展示出的积极疗效与安全性数据。此次获批有望进一步拓宽Krystal Biotech的市场覆盖，并强化其在基因治疗领域的地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154454876","title":"英国MHRA批准Beremagene Geperpavec（Vyjuvek）用于治疗营养不良型大疱性表皮松解症","url":"https://stock-news.laohu8.com/highlight/detail?id=1154454876","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154454876?lang=zh_cn&edition=full","pubTime":"2026-05-16 02:12","pubTimestamp":1778868734,"startTime":"0","endTime":"0","summary":"英国药品和健康产品管理局（MHRA）已正式批准基因疗法Beremagene Geperpavec（商品名Vyjuvek）用于治疗营养不良型大疱性表皮松解症。这一决定为患有此种罕见且严重遗传性皮肤病的患者提供了一种新的治疗选择。\n该疗法由Krystal Biotech Inc.研发，旨在通过局部应用纠正导致皮肤脆弱和水疱形成的基因缺陷。此次批准标志着英国在推进创新基因疗法以应对未满足的医疗需求方面迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168363780","title":"财报前瞻｜Krystal Biotech Inc.本季度营收预计增16.30%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1168363780","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168363780?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:06","pubTimestamp":1777251990,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.将于2026年05月04日发布财报，市场关注Vyjuvek商业放量与利润率走势。综合一致预期显示，本季度Krystal Biotech Inc.营收预计为1.12亿美元，同比增16.30%；调整后每股收益预计为1.39美元，同比增1.92%；息税前利润预计为4,583.62万美元，同比增26.75%。上季度Krystal Biotech Inc.营收为1.07亿美元，同比增长17.52%；毛利率为93.85%；归属于母公司股东的净利润为5,140.00万美元，净利率为47.99%；调整后每股收益为1.70美元，同比增长11.84%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Krystal Biotech Inc.本季度营收预计增16.30%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129093196","title":"Palvella Therapeutics任命罕见病商业领袖Jennifer J. Mcdonough为市场准入与患者服务高级副总裁，强化领导团队","url":"https://stock-news.laohu8.com/highlight/detail?id=1129093196","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129093196?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:35","pubTimestamp":1774265729,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics宣布了一项重要人事任命，罕见病领域的商业领袖Jennifer J. Mcdonough已加入公司，担任市场准入与患者服务高级副总裁。这一举措旨在加强公司的领导团队实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KRYS","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513752603","title":"Krystal Biotech, Inc.2024财年实现净利润89.16百万美元，同比增加715.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513752603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513752603?lang=zh_cn&edition=full","pubTime":"2025-02-24 03:00","pubTimestamp":1740337251,"startTime":"0","endTime":"0","summary":"2月24日，Krystal Biotech, Inc.公布财报，公告显示公司2024财年净利润为89.16百万美元，同比增加715.74%；其中营业收入为2.91亿美元，同比增加473.96%，每股基本收益为3.12美元。从资产负债表来看，Krystal Biotech, Inc.总负债1.09亿美元，其中短期债务1.22百万美元，资产负债比为9.69，流动比率为7.28。机构评级：截至2025年2月24日，当前有9家机构对Krystal Biotech, Inc.目标价做出预测，其中目标均价为211.44美元，其中最低目标价为195.00美元，最高目标价为221.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224030058abd9e675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224030058abd9e675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157840734","title":"异动解读 | 基因疗法公司研发利好 Krystal Biotech Inc.盘中大涨5.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157840734","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157840734?lang=zh_cn&edition=full","pubTime":"2025-02-20 23:00","pubTimestamp":1740063626,"startTime":"0","endTime":"0","summary":"生物科技公司Krystal Biotech Inc.(KRYS)今日盘中大涨5.61%,引发市场广泛关注。\n\n据分析,这主要得益于分析师机构Chardan Capital发布研究报告,维持该公司股票评级为\"买入\",并将目标价从212美元上调至218美元。分析师对该公司前景持乐观态度。\n\nKrystal Biotech Inc.是一家专注于开发新型生物疫苗和基因疗法的临床阶段公司。公司最近在研发方面取得了一定进展,这增强了市场对其长期增长潜力的信心,成为分析师上调评级目标价的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124658988","title":"异动解读 | Krystal Biotech Inc.(KRYS)盘前大涨5.02%，分析师上调评级目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1124658988","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124658988?lang=zh_cn&edition=full","pubTime":"2025-02-20 22:28","pubTimestamp":1740061707,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.(KRYS)今日盘前大涨5.02%,引发市场关注。\n\n分析师机构Chardan Capital发布研报,维持该公司股票评级为\"买入\",同时将目标价从212美元上调至218美元。分析师对该公司前景持乐观态度。\n\nKrystal Biotech是一家临床阶段的基因疗法公司,专注于开发新型生物疫苗。公司最近取得了一些研发进展,这可能是分析师上调评级目标价的主要原因。总体来说,市场对该公司长期增长潜力充满信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Krystal Biotech Inc.(KRYS)盘前大涨5.02%，分析师上调评级目标价","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512448404","title":"Chardan Capital：维持Krystal Biotech(KRYS.US)评级，由买入调整至买入评级, 目标价由212.00美元调整至218.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512448404","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512448404?lang=zh_cn&edition=full","pubTime":"2025-02-20 19:10","pubTimestamp":1740049835,"startTime":"0","endTime":"0","summary":"Chardan Capital：维持Krystal Biotech(KRYS.US)评级，由买入调整至买入评级, 目标价由212.00美元调整至218.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/20191048285027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178376665","title":"异动解读 | Krystal Biotech财报超预期 股价暴涨5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1178376665","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178376665?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:39","pubTimestamp":1739975979,"startTime":"0","endTime":"0","summary":"Krystal Biotech Inc.(纳斯达克代码:KRYS)盘中股价大涨5.85%,引起了资本市场的关注。\n\n导致该股暴涨的主因是Krystal Biotech公布了2024年第四季度财报,实现了业绩超预期。\n\n具体来看,Krystal Biotech2024年第四季度实现每股收益1.52美元,较去年同期快速增长406.67%,并高于分析师普遍预期31.03%。销售额达到91.14百万美元,同比增长116.26%,超出分析师预期0.72%。公司业绩显著增长,销售额和利润率均超过市场预期,让投资者对公司长期发展前景更加看好,从而推动了当日股价大涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KRYS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.krystalbio.com","stockEarnings":[{"period":"1week","weight":0.0176},{"period":"1month","weight":-0.0621},{"period":"3month","weight":0.1019},{"period":"6month","weight":0.2671},{"period":"1year","weight":1.2749},{"period":"ytd","weight":0.35}],"compareEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":0.0325},{"period":"3month","weight":0.0353},{"period":"6month","weight":0.1212},{"period":"1year","weight":0.193},{"period":"ytd","weight":0.1254}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Krystal Biotech, Inc.于2016年4月开始运营。2017年3月，他们从加利福尼亚州有限责任公司转换为特拉华州C-corporation，并将其名称从Krystal Biotech, LLC更改为Krystal Biotech, Inc。该公司是一家专注于为罕见病患者开发和商业化基因药物的生物技术公司。利用他们基于工程化HSV-1的专利平台，他们创造了载体，可以有效地将治疗性转基因传递给多器官系统中感兴趣的细胞。然后，细胞自身的机制转录并翻译编码的效应物来治疗或预防疾病。他们在医疗保健专业人员的办公室或可能由医疗保健专业人员在患者家中制定无创或微创给药途径的载体。他们的目标是开发易于使用的药物，以显著改善患有罕见疾病和慢性疾病的患者的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.012037},{"month":2,"riseRate":0.666667,"avgChangeRate":0.08189},{"month":3,"riseRate":0.555556,"avgChangeRate":0.037905},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.016835},{"month":5,"riseRate":0.555556,"avgChangeRate":0.031146},{"month":6,"riseRate":0.777778,"avgChangeRate":0.125274},{"month":7,"riseRate":0.666667,"avgChangeRate":0.059124},{"month":8,"riseRate":0.111111,"avgChangeRate":-0.012466},{"month":9,"riseRate":0.25,"avgChangeRate":-0.037914},{"month":10,"riseRate":0.555556,"avgChangeRate":0.053086},{"month":11,"riseRate":0.888889,"avgChangeRate":0.190014},{"month":12,"riseRate":0.555556,"avgChangeRate":-0.011676}],"exchange":"NASDAQ","name":"Krystal Biotech Inc.","nameEN":"Krystal Biotech Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Krystal Biotech Inc.(KRYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Krystal Biotech Inc.(KRYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Krystal Biotech Inc.,KRYS,Krystal Biotech Inc.股票,Krystal Biotech Inc.股票老虎,Krystal Biotech Inc.股票老虎国际,Krystal Biotech Inc.行情,Krystal Biotech Inc.股票行情,Krystal Biotech Inc.股价,Krystal Biotech Inc.股市,Krystal Biotech Inc.股票价格,Krystal Biotech Inc.股票交易,Krystal Biotech Inc.股票购买,Krystal Biotech Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Krystal Biotech Inc.(KRYS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Krystal Biotech Inc.(KRYS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}